The US based Cytori Therapeutics has developed a new device based on the Celution System which will enable the researchers to use the fat tissue of the patients to turn into a regenerative cell cocktail for the use of medical procedures or for future use. Unlike the embryonic stem cell research the procedure is expected to be free from any controversy. Also the process of removing a little unwanted fat from patients is good in itself. The company has been successful in the research procedure so far. The company recorded its first product revenue during 1Q08 of $153,000 related to sales of the Celution System.

Cytori opted for a tie up with the Japan-based strategic partner Green Hospital Supply, which specializes in distribution agreements with hospitals for Cytori’s stem cell banking business. Cytori has received an additional funding of $6 million at the end of April. Green Hospital Supply now owns 3 million shares of Cytori. Cytori issued guidance for full-year product revenues between $10 to $12 million based on initial demand from the European and Asian reconstructive surgery market.

It can be recalled that Cytori has recorded its first successful application of its study in Japan using the company’s proprietary Celution System output of adipose-derived stem and regenerative cells for breast augmentation. The company is hoping for another success in 2009 with a nine-month follow-up, at which time volume retention and tissue softness will be measured to determine if the results persist and can be considered permanent. The study is being conducted on 20 patients as a new cosmetic surgery option for small-volume breast augmentation, with the goal of achieving both lasting and natural results. Cytori plans to develop the significant longer-term market opportunity for cardiovascular and heart disease on its own. However the attempt needs to be supported by development and product revenue over the next few years.

Source:The Alpha